Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC1TE
2022-502038-23-00Phase 2Authorised
- Sponsor
- Gentofte Hospital
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) and atherosclerotic disease comparing Colrefuz (colchicine) with Placebo for colchicine (2 arms). Primary endpoint: High-sensitivity C-reactive protein at 26 weeks. Planned start Jan 2023; status: authorised.
02
Drugs
colchicine
03
Conditions
diabetes mellitus type 1 (T1D)atherosclerotic disease
Beyond the preview
Go deeper on 2022-502038-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502038-23-00.